Kura Oncology Inc（KURA）财务数据KURAKura Oncology Inc

Evaluating the bottom line, Kura Oncology, Inc. maintains a gross margin of 98.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -349.77%, while the net margin is -327.33%. These profitability ratios, combined with a Return on Equity (ROE) of -167.71%, provide a clear picture of how effectively KURA converts its operational activities into shareholder value.

In the context of the broader market, KURA competes directly with industry leaders such as GLUE and JANX. With a market capitalization of $966.11M, it holds a significant position in the sector. When comparing efficiency, KURA's gross margin of 98.84% stands against GLUE's 100.00% and JANX's 100.00%. Such benchmarking helps identify whether Kura Oncology, Inc. is trading at a premium or discount relative to its financial performance.

Kura's revenue for Q2 2026 was $20.87 million, with a gross margin of 98.84%. Despite the losses, the company has shown strong sales growth for its drug KOMZIFTI, which generated $9.1 million in Q2, a 57% increase from the previous quarter.